Tandem Diabetes Care (TNDM) PT Raised to $102 at Oppenheimer Due to Control-IQ Success
Tweet Send to a Friend
Oppenheimer analyst Steven Lichtman raised the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $102.00 (from $92.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
